Modeling omics dose-response at the pathway level with DoseRider

The generation of omics data sets has become an important approach in modern pharmacological and toxicological research as it can provide mechanistic and quantitative information on a large scale. Analyses of these data frequently revealed a non-linear dose-response relationship underscoring the imp...

Full description

Saved in:
Bibliographic Details
Main Authors: Pablo Monfort-Lanzas, Johanna M. Gostner, Hubert Hackl
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Computational and Structural Biotechnology Journal
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2001037025001266
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849764515033382912
author Pablo Monfort-Lanzas
Johanna M. Gostner
Hubert Hackl
author_facet Pablo Monfort-Lanzas
Johanna M. Gostner
Hubert Hackl
author_sort Pablo Monfort-Lanzas
collection DOAJ
description The generation of omics data sets has become an important approach in modern pharmacological and toxicological research as it can provide mechanistic and quantitative information on a large scale. Analyses of these data frequently revealed a non-linear dose-response relationship underscoring the importance of the modeling process to infer biological exposure limits. A number of tools have been developed for dose-response modeling and various thresholds have been defined as a quantitative representation of the effect of a substance, such as effective concentrations or benchmark doses (BMD). Here we present DoseRider an easy-to-use web application and a companion R package for linear and non-linear dose-response modeling and assessment of BMD at the level of biological pathways or signatures using generalized mixed effect models. This approach allows to analyze custom or provided multi-omics data such as RNA sequencing or metabolomics data and its annotation of a collection of pathways and gene sets from various species. Moreover, we introduce the concept of the trend change doses (TCDs) as a numerical descriptor of effects derived from complex dose-response curves. The usability of DoseRider was demonstrated by analyses of RNA sequencing data of bisphenol AF (BPAF) treatment of a human breast cancer cell line (MCF-7) at 8 different concentrations using gene sets for chemical and genetic perturbations (MSigDB). The BMD for BPAF and a set of genes upregulated by estrogen in breast cancer was 0.2 µM (95 %-CI 0.1–0.5 µM) and the lowest TCD (TCD1) was 0.003 µM (95 %-CI 0.0006–0.01 µM). The comprehensive presentation of the results underlines the suitability of the system for pharmacogenomics, toxicogenomics, and applications beyond.
format Article
id doaj-art-8cd4175e04f44d3fbc1fa9d8df9b5af7
institution DOAJ
issn 2001-0370
language English
publishDate 2025-01-01
publisher Elsevier
record_format Article
series Computational and Structural Biotechnology Journal
spelling doaj-art-8cd4175e04f44d3fbc1fa9d8df9b5af72025-08-20T03:05:07ZengElsevierComputational and Structural Biotechnology Journal2001-03702025-01-01271440144810.1016/j.csbj.2025.04.004Modeling omics dose-response at the pathway level with DoseRiderPablo Monfort-Lanzas0Johanna M. Gostner1Hubert Hackl2Institute of Medical Biochemistry, Biocenter, Medical University Innsbruck, 6020 Innsbruck, Austria; Institute of Bioinformatics, Biocenter, Medical University Innsbruck, 6020 Innsbruck, AustriaInstitute of Medical Biochemistry, Biocenter, Medical University Innsbruck, 6020 Innsbruck, Austria; Corresponding authors.Institute of Bioinformatics, Biocenter, Medical University Innsbruck, 6020 Innsbruck, Austria; Corresponding authors.The generation of omics data sets has become an important approach in modern pharmacological and toxicological research as it can provide mechanistic and quantitative information on a large scale. Analyses of these data frequently revealed a non-linear dose-response relationship underscoring the importance of the modeling process to infer biological exposure limits. A number of tools have been developed for dose-response modeling and various thresholds have been defined as a quantitative representation of the effect of a substance, such as effective concentrations or benchmark doses (BMD). Here we present DoseRider an easy-to-use web application and a companion R package for linear and non-linear dose-response modeling and assessment of BMD at the level of biological pathways or signatures using generalized mixed effect models. This approach allows to analyze custom or provided multi-omics data such as RNA sequencing or metabolomics data and its annotation of a collection of pathways and gene sets from various species. Moreover, we introduce the concept of the trend change doses (TCDs) as a numerical descriptor of effects derived from complex dose-response curves. The usability of DoseRider was demonstrated by analyses of RNA sequencing data of bisphenol AF (BPAF) treatment of a human breast cancer cell line (MCF-7) at 8 different concentrations using gene sets for chemical and genetic perturbations (MSigDB). The BMD for BPAF and a set of genes upregulated by estrogen in breast cancer was 0.2 µM (95 %-CI 0.1–0.5 µM) and the lowest TCD (TCD1) was 0.003 µM (95 %-CI 0.0006–0.01 µM). The comprehensive presentation of the results underlines the suitability of the system for pharmacogenomics, toxicogenomics, and applications beyond.http://www.sciencedirect.com/science/article/pii/S2001037025001266Benchmark doseDose-response modelingMixed modelsMulti-omicsSystem biologyTrend change dose
spellingShingle Pablo Monfort-Lanzas
Johanna M. Gostner
Hubert Hackl
Modeling omics dose-response at the pathway level with DoseRider
Computational and Structural Biotechnology Journal
Benchmark dose
Dose-response modeling
Mixed models
Multi-omics
System biology
Trend change dose
title Modeling omics dose-response at the pathway level with DoseRider
title_full Modeling omics dose-response at the pathway level with DoseRider
title_fullStr Modeling omics dose-response at the pathway level with DoseRider
title_full_unstemmed Modeling omics dose-response at the pathway level with DoseRider
title_short Modeling omics dose-response at the pathway level with DoseRider
title_sort modeling omics dose response at the pathway level with doserider
topic Benchmark dose
Dose-response modeling
Mixed models
Multi-omics
System biology
Trend change dose
url http://www.sciencedirect.com/science/article/pii/S2001037025001266
work_keys_str_mv AT pablomonfortlanzas modelingomicsdoseresponseatthepathwaylevelwithdoserider
AT johannamgostner modelingomicsdoseresponseatthepathwaylevelwithdoserider
AT huberthackl modelingomicsdoseresponseatthepathwaylevelwithdoserider